Intracellular molecular effects of insulin resistance in patients with metabolic syndrome

Evasio Pasini, Vincenzo Flati, Silvia Paiardi, Damiano Rizzoni, Enzo Porteri, Roberto Aquilani, Deodato Assanelli, Giovanni Corsetti, Silvia Speca, Rita Rezzani, Carolina De Ciuceis, Enrico Agabiti-Rosei

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Aim of the study: Patients with metabolic syndrome (MetS) have an increased risk of cardiovascular disease. Data obtained from muscle biopsies have demonstrated altered insulin signaling (IS) in patients with MetS. The IS regulates critical cell functions including molecular-regulated cellular metabolite fluxes, protein and energetic metabolism, cell proliferation and apoptosis with consequent regulation of cell life including endothelial homeostasis and blood coagulation. However, little is known about blood cell IS in MetS patients. The aim of this study was to develop a method to evaluate IS in peripheral lymphocytes to identify altered intracellular molecules in patients with MetS to use as risk biomarkers of vascular thrombosis.Patients and Methods: We investigated 40 patients with MetS and 20 controls. MetS was defined according to guidelines from the US National Cholesterol Education Program Adult Treatment Panel III. Blood samples were taken from all participants. Total mononuclear cells were isolated from peripheral blood using density gradient centrifugation. IS molecules were evaluated using Western blot analysis followed by computer-assisted densitometer evaluation.Results: Lymphocytes of MetS patients showed a reduced mTOR expression (the mammalian target of rapamycin) which is a fundamental molecule of IS. Major impairment of IS was confirmed by reduced upstream and downstream mTOR molecules which regulate fundamental cells metabolic functions.Conclusions: In patients with MetS, we found a reduction of mTOR and other mTOR-related molecules involved in insulin resistance, cell repair, coagulation and vasculogenesis. A reduced expression of mTOR may reflect an increased risk of vascular thrombosis.

Original languageEnglish
Article number46
JournalCardiovascular Diabetology
Volume9
DOIs
Publication statusPublished - Sep 1 2010

Fingerprint

Insulin Resistance
Insulin
Blood Vessels
Thrombosis
Lymphocytes
Density Gradient Centrifugation
Blood Coagulation
Sirolimus
Blood Cells
Homeostasis
Cardiovascular Diseases
Biomarkers
Western Blotting
Cholesterol
Cell Proliferation
Guidelines
Apoptosis
Biopsy
Education
Muscles

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Intracellular molecular effects of insulin resistance in patients with metabolic syndrome. / Pasini, Evasio; Flati, Vincenzo; Paiardi, Silvia; Rizzoni, Damiano; Porteri, Enzo; Aquilani, Roberto; Assanelli, Deodato; Corsetti, Giovanni; Speca, Silvia; Rezzani, Rita; De Ciuceis, Carolina; Agabiti-Rosei, Enrico.

In: Cardiovascular Diabetology, Vol. 9, 46, 01.09.2010.

Research output: Contribution to journalArticle

Pasini, E, Flati, V, Paiardi, S, Rizzoni, D, Porteri, E, Aquilani, R, Assanelli, D, Corsetti, G, Speca, S, Rezzani, R, De Ciuceis, C & Agabiti-Rosei, E 2010, 'Intracellular molecular effects of insulin resistance in patients with metabolic syndrome', Cardiovascular Diabetology, vol. 9, 46. https://doi.org/10.1186/1475-2840-9-46
Pasini, Evasio ; Flati, Vincenzo ; Paiardi, Silvia ; Rizzoni, Damiano ; Porteri, Enzo ; Aquilani, Roberto ; Assanelli, Deodato ; Corsetti, Giovanni ; Speca, Silvia ; Rezzani, Rita ; De Ciuceis, Carolina ; Agabiti-Rosei, Enrico. / Intracellular molecular effects of insulin resistance in patients with metabolic syndrome. In: Cardiovascular Diabetology. 2010 ; Vol. 9.
@article{cc0e5e5f61e7454f9b28c1f512af6672,
title = "Intracellular molecular effects of insulin resistance in patients with metabolic syndrome",
abstract = "Aim of the study: Patients with metabolic syndrome (MetS) have an increased risk of cardiovascular disease. Data obtained from muscle biopsies have demonstrated altered insulin signaling (IS) in patients with MetS. The IS regulates critical cell functions including molecular-regulated cellular metabolite fluxes, protein and energetic metabolism, cell proliferation and apoptosis with consequent regulation of cell life including endothelial homeostasis and blood coagulation. However, little is known about blood cell IS in MetS patients. The aim of this study was to develop a method to evaluate IS in peripheral lymphocytes to identify altered intracellular molecules in patients with MetS to use as risk biomarkers of vascular thrombosis.Patients and Methods: We investigated 40 patients with MetS and 20 controls. MetS was defined according to guidelines from the US National Cholesterol Education Program Adult Treatment Panel III. Blood samples were taken from all participants. Total mononuclear cells were isolated from peripheral blood using density gradient centrifugation. IS molecules were evaluated using Western blot analysis followed by computer-assisted densitometer evaluation.Results: Lymphocytes of MetS patients showed a reduced mTOR expression (the mammalian target of rapamycin) which is a fundamental molecule of IS. Major impairment of IS was confirmed by reduced upstream and downstream mTOR molecules which regulate fundamental cells metabolic functions.Conclusions: In patients with MetS, we found a reduction of mTOR and other mTOR-related molecules involved in insulin resistance, cell repair, coagulation and vasculogenesis. A reduced expression of mTOR may reflect an increased risk of vascular thrombosis.",
author = "Evasio Pasini and Vincenzo Flati and Silvia Paiardi and Damiano Rizzoni and Enzo Porteri and Roberto Aquilani and Deodato Assanelli and Giovanni Corsetti and Silvia Speca and Rita Rezzani and {De Ciuceis}, Carolina and Enrico Agabiti-Rosei",
year = "2010",
month = "9",
day = "1",
doi = "10.1186/1475-2840-9-46",
language = "English",
volume = "9",
journal = "Cardiovascular Diabetology",
issn = "1475-2840",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Intracellular molecular effects of insulin resistance in patients with metabolic syndrome

AU - Pasini, Evasio

AU - Flati, Vincenzo

AU - Paiardi, Silvia

AU - Rizzoni, Damiano

AU - Porteri, Enzo

AU - Aquilani, Roberto

AU - Assanelli, Deodato

AU - Corsetti, Giovanni

AU - Speca, Silvia

AU - Rezzani, Rita

AU - De Ciuceis, Carolina

AU - Agabiti-Rosei, Enrico

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Aim of the study: Patients with metabolic syndrome (MetS) have an increased risk of cardiovascular disease. Data obtained from muscle biopsies have demonstrated altered insulin signaling (IS) in patients with MetS. The IS regulates critical cell functions including molecular-regulated cellular metabolite fluxes, protein and energetic metabolism, cell proliferation and apoptosis with consequent regulation of cell life including endothelial homeostasis and blood coagulation. However, little is known about blood cell IS in MetS patients. The aim of this study was to develop a method to evaluate IS in peripheral lymphocytes to identify altered intracellular molecules in patients with MetS to use as risk biomarkers of vascular thrombosis.Patients and Methods: We investigated 40 patients with MetS and 20 controls. MetS was defined according to guidelines from the US National Cholesterol Education Program Adult Treatment Panel III. Blood samples were taken from all participants. Total mononuclear cells were isolated from peripheral blood using density gradient centrifugation. IS molecules were evaluated using Western blot analysis followed by computer-assisted densitometer evaluation.Results: Lymphocytes of MetS patients showed a reduced mTOR expression (the mammalian target of rapamycin) which is a fundamental molecule of IS. Major impairment of IS was confirmed by reduced upstream and downstream mTOR molecules which regulate fundamental cells metabolic functions.Conclusions: In patients with MetS, we found a reduction of mTOR and other mTOR-related molecules involved in insulin resistance, cell repair, coagulation and vasculogenesis. A reduced expression of mTOR may reflect an increased risk of vascular thrombosis.

AB - Aim of the study: Patients with metabolic syndrome (MetS) have an increased risk of cardiovascular disease. Data obtained from muscle biopsies have demonstrated altered insulin signaling (IS) in patients with MetS. The IS regulates critical cell functions including molecular-regulated cellular metabolite fluxes, protein and energetic metabolism, cell proliferation and apoptosis with consequent regulation of cell life including endothelial homeostasis and blood coagulation. However, little is known about blood cell IS in MetS patients. The aim of this study was to develop a method to evaluate IS in peripheral lymphocytes to identify altered intracellular molecules in patients with MetS to use as risk biomarkers of vascular thrombosis.Patients and Methods: We investigated 40 patients with MetS and 20 controls. MetS was defined according to guidelines from the US National Cholesterol Education Program Adult Treatment Panel III. Blood samples were taken from all participants. Total mononuclear cells were isolated from peripheral blood using density gradient centrifugation. IS molecules were evaluated using Western blot analysis followed by computer-assisted densitometer evaluation.Results: Lymphocytes of MetS patients showed a reduced mTOR expression (the mammalian target of rapamycin) which is a fundamental molecule of IS. Major impairment of IS was confirmed by reduced upstream and downstream mTOR molecules which regulate fundamental cells metabolic functions.Conclusions: In patients with MetS, we found a reduction of mTOR and other mTOR-related molecules involved in insulin resistance, cell repair, coagulation and vasculogenesis. A reduced expression of mTOR may reflect an increased risk of vascular thrombosis.

UR - http://www.scopus.com/inward/record.url?scp=77956476507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956476507&partnerID=8YFLogxK

U2 - 10.1186/1475-2840-9-46

DO - 10.1186/1475-2840-9-46

M3 - Article

C2 - 20809949

AN - SCOPUS:77956476507

VL - 9

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

SN - 1475-2840

M1 - 46

ER -